0001493152-26-018910
SEC filingDSS, Inc., a multi-segment operating company focused on packaging, biotechnology, and financial services, is offering up to 8.33 million shares of common stock at an assumed price of $0.96 per share to raise approximately $7.05 million for working capital.
DSS, Inc. is a diversified holding company with operations spanning product packaging, biotechnology, commercial lending, and securities brokerage. The Company's Product Packaging segment, operated through Premier Packaging Corporation, provides custom packaging solutions, while the Biotechnology segment includes a controlling interest in Impact BioMedical Inc. (NYSE American: IBO). The Securities and Investment Management segment includes Sentinel Brokers Company, Inc., a FINRA-registered broker-dealer. This multi-segment structure exposes the Company to diverse market risks but also provides multiple avenues for value creation.
The financial profile of DSS reflects significant operational challenges. As of December 31, 2025, the Company reported an accumulated deficit of approximately $327 million and a negative net tangible book value of $10.1 million. The Company has a history of operating losses and faces liquidity constraints, evidenced by a $37 million loan related to its AMRE LifeCare subsidiary being in default as of the filing date. Cash and equivalents stood at $6.2 million as of December 31, 2025. Revenue concentration is a critical concern, with a single customer accounting for 29% of consolidated revenue.
The proposed offering involves the sale of 8,333,333 shares of common stock at an assumed price of $0.96 per share, alongside Pre-Funded Warrants. The offering is expected to generate net proceeds of approximately $7.05 million, which will be used for working capital and general corporate purposes. The placement agent, Aegis Capital Corp., will receive a 7.0% fee plus a 1.0% non-accountable expense allowance. Purchasers in the offering will experience immediate dilution of $1.13 per share, with the as-adjusted net tangible book value remaining negative at ($0.17) per share.
Governance is heavily concentrated. Heng Fai Ambrose Chan, through direct ownership and control of entities like Alset Inc. and Alset International Limited, beneficially owns 61.2% of the outstanding common stock. This concentration effectively allows him to control corporate actions requiring stockholder approval. The Company is also subject to significant risks related to its internal controls, having identified material weaknesses in its financial reporting structure. Additionally, the Company has substantial potential share overhang from convertible notes and warrants, with over 20 million shares potentially issuable upon conversion and exercise of related party instruments.